Product Description
Indications:
Amoxy is indicated for the treatment of infections due to susceptible strains of the sensitive organisms: Gram-negative: H. influenzae, E. coli, Pr. mirabilis, and N. gonorrhoeae. Gram-positive: Streptococcus species, D. pneumoniae, and non-penicillinase producing Staphylococci.
Contra-indications:
Individuals with a history of an allergic reaction to the peni. It is also contraindicated in patients with a history of amoxi associated hepatic dysfunction of jaundice.
Adverse Reactions:
Sensitivity reactions are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever or urticaria. The hypersensitivity reactions are Erythematous maculopapular rashes, urticaria, fever and joint pains. Anaphylactic shock may occur. Gastrointestinal :diarrhoea, nausea, vomiting, heartburn, pseudomembranous colitis Liver: A moderate rise in serum glutamic oxalacetic transaminase has been noted, but the significance of this finding is unknown. Haemic and Lymphatic Systems: Anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia and granulocytopenia have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Central Nervous System: Reversible hyperactivity, agitation, anxiety, confusion, behavioural changes and/or dizziness.
Precautions:
Hypersensitivity reactions: Erythrematous maculopapular rashes, urticaria, erythema multiforme and exfoliative dermatitis. Whenever such reactions occur, Amoxi should be discontinued. Hepatic: A moderate rise in AST has been noted, but the significance of this finding is unknown. Haematologic: Reactions such as anaemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leucopenia and agranulocytosis have been reported during therapy with other penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.
Dosage and Administration:
Upper respiratory tract infections (due to Streptococci, pneumococci, non-penicillinase producing Staphylococci and H. influenzae);
Genito-urinary tract infections (due to E. coli, Proteus mirabilis and Strep. faecalis);
Skin and Skin Structure infections (due to Streptococci, sensitive Staphylococci and E. coli). Adults: 250 mg every eight hours. Children: (under 20 kg): 25 mg/kg/day in equally divided doses every eight hours. In severe infections or those caused by less susceptible organisms, 500 mg every eight hours for adults and 50 mg/kg/ day in equally divided doses every 8 hours for children may be needed.
Lower respiratory tract infections (due to Streptococci, pneumococci, non-penicillinase producing Staphylococci and H. influenzae). Adults: 500 mg every eight hours. Children: (under 20 kg): 50 mg/kg/day in equally divided doses every eight hours.
Urethritis (due to N. gonorrhoeae). Adults: 3 grams as a single dose. Cases of gonorrhoea with a suspected lesion of syphilis should have dark field examinations before receiving Amoxi and monthly serological tests for a minimum of four months.
Acute, uncomplicated lower urinary tract infections (due to E. coli, Proteus mirabilis, Strep. faecalis and non¬penicillinase producing Staphylococci). Adults: 3 grams as a single dose. Note: The children's dosage is intended for individuals whose weight will not cause the dosage to be calculated greater than that recommended for adults. Children weighing more that 20 kg should be dosed according to the adult recommendations. In renal Impairment the excretion of the antibiotic will be delayed, and depending on the degree of impairment, it may be necessary to reduce the total daily dosage.
Audited Supplier 
){kind=link}